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Abstract: Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression 
is reduced in osteosarcoma cells, one of the most common types of bone tumor. miR-199a-3p 
exhibited functions of tumor cell growth inhibition, suggesting the potential application of 
miR-199a-3p as an anticancer agent. In the study reported here, we designed and developed a 
lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and 
determined the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells. 
In addition, another potent miR, let-7a, which also displayed tumor suppressive ability, was 
selected as a candidate miR for evaluation. Fluorescence microscopy studies and real-time 
polymerase chain reaction results showed that dextran nanoparticles could deliver both miR-
199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully. Western blot-
ting analysis and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays 
demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the 
expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma 
cells. These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle 
platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.
Keywords: bone tumor, dextran nanoparticles, miR-199a-3p, let-7a, RNAi
Introduction
Osteosarcoma is the most common primary malignant tumor of bone. It usually 
occurs in the developing bones of children and adolescents.1 Currently, the treatment 
of osteosarcoma involves surgery, radiation therapy, and adjuvant chemotherapy.2 
Despite recent advances in chemotherapy, the 5-year event-free survival and overall 
survival rates are still around 60%.2,3 Furthermore, drug resistance to chemotherapy 
frequently develops in osteosarcoma and dose-limiting toxicity restricts the utility of 
chemotherapeutic drugs. Thus, more selective and effective therapeutic strategies are 
required for the treatment of osteosarcoma.3–6
Recent years have seen remarkable progress made in basic understanding of the 
disease and in deciphering the role of microRNAs (miRs) in cancer. “miRs” are a sub-
set of small noncoding RNA molecules that influence tumor formation, maintenance, 
metastasis, apoptosis, and drug resistance. Mature miRs bind to the 3′ untranslated 
regions of target genes and inhibit gene expression by degradation or repress translation 
of the target messenger RNA. There has been great interest in the function of miRs 
in human cancers and numerous studies have observed the dysregulation of miRs in 
different tumors, including osteosarcoma.7–12 In this regard, we recently demonstrated 
that the expression of miR-199a-3p is remarkably decreased in osteosarcoma cell lines. 
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The transfection of miR-199a-3p into osteosarcoma cells can 
significantly decrease cell growth and proliferation.11 The 
expression of miR-199a-3p is also downregulated in several 
human malignancies including colon and hepatocellular 
carcinoma.13–15 Restoring the expression of miR-199a-3p 
in these tumor cells led to a reduced invasive capability of 
cancer cells and increased sensitivity to chemotherapeutic 
drugs.13 These results suggest that miR-199a-3p can be used 
as a potential treatment target for such cancers. Similarly, 
another tumor suppressor miR, let-7a, has been found down-
regulated or completely repressed in many types of human 
cancers.16–19 Accordingly, the restoration of let-7a expression 
has been found to inhibit the proliferation of many cancer 
cells.17,20–23 Thus, the exogenous transfection of specific miR 
into tumor cells may open up newer avenues for the effective 
treatment of several human cancers.
Although miR-based anticancer strategies are emerging 
as a highly promising therapeutic approach, their systemic 
delivery still remains a great challenge. Similar to small inter-
fering RNA (siRNA) molecules, miRs are highly unstable 
in the cell environment and must be delivered by effective 
carrier vectors.24 While viral vectors may also be used for 
proof-of-concept experimental approaches to the cellular 
delivery of miRs, safe and efficient nonviral delivery systems 
are required in order to translate their utility into clinically 
viable therapeutic strategies that can benefit cancer patients. 
In this regard, polymeric nanoparticle-based delivery serves 
as a promising platform with several advantages, including 
higher transfection efficiencies, targeted delivery, and ease of 
modification or functionalization, and has the added benefit 
of safety and nontoxicity.25 Several reports have shown that 
miRs can be delivered into the cancer cell by nano-sized non-
viral vectors. For example, liposome-polycation-hyaluronic 
acid modified with a GC4 single-chain variable antibody 
(scFv) was used to deliver miR-34a into B16F10 lung cancer 
cells.26 Cysteamine-functionalized gold nanoparticles were 
able to deliver miRs into two different tumor models, and 
the results showed that a 96% transfection rate of miRs into 
cells was achieved and 98% of cells showed good viabil-
ity following treatment. The data also showed these gold 
nanoparticles had a ten- to 20-fold higher payload capacity 
than Lipofectamine®.27 Several novel nanotechnology-based 
miR/siRNA delivery platforms are still in the early stages 
of development.28–30
In our previous studies, we used dextran as a starting 
block for the fabrication of nanosystems because the base 
polymer of dextran is a glucan-based nontoxic material that 
has been approved as a plasma expander for human use by 
the US Food and Drug Administration. We also demon-
strated that a dextran backbone can be functionalized with 
lipid chains to enable self-assembly to form nanoparticles.31 
In different cancer model systems, dextran-based nano-
particles have been able to transport drugs and multidrug 
resistance (MDR1) siRNA efficiently into tumor cells to 
overcome drug resistance.32,33 We hypothesize that dextran-
based nanoparticles could also be an ideal carrier for the 
delivery of therapeutic miRs into cancer cells. In the study 
reported here, we employed miR-199a-3p and let-7a as 
candidate miRs to determine the efficiency of miR delivery 
in osteosarcoma cells using a dextran-based self-assembling 
nanoparticle platform.
Materials and methods
The chemical reagents and polymers for synthesis, such 
as dextran, stearyl amine, cystamine, pyridine, sodium 
periodate, sodium cyanoborohydride, potassium sulfate, and 
azo-bis-isobutyronitrile were purchased from Sigma-Aldrich 
Co (St Louis, MO, USA). Dithiol-modified poly(ethylene 
glycol) (PEG-[SH]
2
, molecular weight (MW) 2,000) was 
purchased from SunBio, Inc. (Seoul, South Korea). Anhydrous 
lithium chloride (LiCl) was from Fisher Scientific (Philadel-
phia, PA, USA). Dehydrated  dimethyl formamide (DMF) 
and dimethyl sulfoxide (DMSO) with molecular sieves were 
obtained from Acros Organics (Parsipanny, NJ, USA). Acry-
loyl chloride, pyridine, and other reagents and solvents were 
from Sigma-Aldrich Co and were used as received without 
further purification.
synthesis of dextran acrylate
The synthesis of dextran acrylate was based on a previously 
described procedure with modifications.31 In brief, a fixed 
amount of dextran (MW ~40 kDa, 2 g) was added to an 
LiCl/DMF (4% w/v, 50 mL) solvent mixture in a round-
bottom flask (200 mL). The temperature of the oil bath was 
raised from room temperature to 120°C over a period of 2 
hours. The resultant mixture became a homogeneous golden-
yellow-colored solution. The solution was cooled to room 
temperature, and pyridine (500 µL) was added and stirred. 
The reaction mixture was cooled to 0°C using an ice bath, 
and varying amounts of acryloyl chloride (1.0–1.5 molar 
excess) was added drop-wise using an addition funnel. The 
reaction was maintained at 0°C until total addition of acryloyl 
chloride was complete, over a period of 1–2 hours. The reac-
tion was allowed to continue overnight with stirring.
The dextran acrylate obtained was precipitated in 
excess cold ethanol and washed three times with absolute 
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ethanol. For confirmation of the formation of dextran 
acrylate, a small portion of the acrylate monomer was 
polymerized using 0.001% azo-bis-isobutyronitrile ini-
tiator in DMSO at 60°C for 24 hours, which resulted in 
formation of the acrylate polymer, confirming the reaction. 
Alternately, for lipid modification, the dextran acrylate 
was directly used as the monomer for the next step, in a 
one-pot synthesis.
Synthesis of lipid-modified dextran
Dextran acrylate synthesized in the previously described step 
was dissolved in dry DMF and stirred in a glass vial with 
varying amounts (5–10 mole %) of stearyl amine and a cata-
lyst (0.01 mole % AlCl
3
). The reaction mixture was heated to 
40°C–50°C in an oil bath for 24 hours. The product obtained 
(stearyl amine-modified dextran) was precipitated and 
washed in cold ethanol several times to purify the product. 
Finally, the lipid-modified dextran derivative was dissolved 
in a small amount of deionized water and lyophilized to 
yield the pale-yellow-colored final product. The stearyl 
modification of dextran was confirmed by nuclear magnetic 
resonance spectroscopy and the percent lipid modification 
was estimated to be 5–7 mole %.
synthesis of thiolated dextran
The dextran backbone was oxidized based on a reported pro-
cedure.34 In brief, NaIO
4
 was dissolved in 60 mL of deionized 
water. The solution was added to a solution containing 4 g 
of dextran in 30 mL of deionized water. The reaction was 
stirred in the dark for 2 hours at room temperature. At the end 
of the reaction, the solution was dialysed extensively against 
deionized water, using Spectra/Por® dialysis membranes 
(MW cutoff 12–14 kDa; Spectrum Labs, Rancho Dominguez, 
CA, USA) extensively against deionized water (2 L) for 
4 days with several water replacements. A powdery, free-
flowing sample was obtained after freeze-drying (yield 3.7 g 
[92.5%]).
A 500 mg portion of the oxidized dextran was dissolved 
in 50 mL of pH 5.2 buffer containing K
2
SO
4
 and NaCNBH
3
. 
Then, 50 mg of cystamine was added and the mixture 
stirred at 40°C for 4 days. The product was subjected to 
extensive dialysis and then lyophilized to yield thiolated 
dextran. All compounds synthesized were routinely charac-
terized by high-performance liquid chromatography, liquid 
chromatography–mass spectrometry, proton- and carbon-13 
nuclear magnetic resonance spectroscopy, Elman assay, and 
Fourier transform infrared spectroscopy to assure chemical 
identity and purity.
encapsulation of microrNas 
in functionalized dextran-based 
nanoparticles
The miR-containing dextran nanoparticles were fabricated in 
a similar fashion to the siRNA-loaded dextran nanosystems 
reported by our group recently.32,33 Briefly, a stock solution 
of 5 mg/mL (~2.5 mM) dextran thiol, 5 mg/mL (~2.5 mM) 
dextran hexylamine, 5 mg/mL (125 µM) PEG-thiol, and 
2 µM miR solution was prepared. For obtaining a 100 nM 
miR concentration, a 120 µL stock solution of miR was 
mixed with 40 µL of dextran-thiol stock solution using a 
vortex shaker. It was then incubated for 5 minutes. To this 
mixture, 40 µL of dextran-hexylamine derivatives were 
added and incubated for another 5 minutes. Finally, 40 µL of 
PEG-(SH)
2
 was added and incubated for another 15 minutes 
to form the PEGylated nanoparticles.
This method of sequential addition was used so that the 
miR would be entrapped in the interpenetrating dextran 
hydrogel network. Further, a PEG-thiol derivative was used 
to form intermolecular cross-linking of individual nanopar-
ticles decorated with PEG on the surface. The final mixture 
was subsequently diluted with the medium and applied at 
the designated concentrations. Nanoparticles containing 
100 nM of nonspecific miRs were used as negative controls 
in the experiments.
Measurement of size and zeta potentials, 
and transmission electron microscopy of 
microrNa-loaded dextran nanoparticles
The particle size and zeta potentials of the miR-199a-3p- 
loaded dextran nanoparticles were determined with a 
Zetasizer Nano S (Malvern Instruments Ltd, Malvern, UK). 
For light-scattering experiments, the samples were measured 
at fixed angle of 90° at 25°C. The scattering intensity was 
adjusted in the range of 50–200 kcps by diluting the samples 
with phosphate-buffered saline (PBS). For zeta potentials, 
the default parameters of dielectric constant, refractive index, 
and viscosity of water were used based on the electropho-
retic mobility of the nanoparticles. Transmission electron 
micrographs of nanoparticles were obtained using a JEM-
1000 Ultra High Voltage Electron Microscope (JEOL Ltd, 
Tokyo, Japan).
cell culture and reagents
Osteosarcoma cell lines, KHOS and U-2OS, were cultured 
with Dulbecco’s Modified Eagle’s Medium (DMEM), supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin, and 
100 U/mL streptomycin (Thermo Fisher Scientific, Waltham, 
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MA, USA). The cells were incubated at 37°C in a 5% CO
2
, 95% 
air atmosphere. The fluorescent-labeled AF488-miR-199a-3p 
(sequences: 5′-ACAGUAGUCUGCACAUUGGUUA-3′, 
green color) and A546-labeled let-7a (sequences: 
5′-UGAGGUAGUAGGUUGUAUAGUU-3′, red color) 
were purchased from Qiagen NV (Venlo, the Netherlands). 
The unlabeled miR-199a-3p, let-7a, nonspecific miR mimic, 
and Life Technologies Lipofectamine® RNAiMAX were 
purchased from Thermo Fisher Scientific.
Determination of microrNa cellular 
uptake by dextran nanoparticles
Evaluation of the cellular uptake of miR was based on a 
previously described procedure.35 In brief, osteosarcoma 
cell lines U-2OS and KHOS were seeded at density of 1×105 
cells/well in 24-well plates (three wells per cell line). After 
24 hours’ incubation, 100 nM AF488-miR-199a-3p, or A546-
let-7a encapsulated in dextran-based nanoparticles or 
transfected with Lipofectamine® RNAiMAX (Invitrogen); or 
100 nM AF488-miR-199a-3p or A546-let-7a alone without 
nanoparticles were added into each well of cultured U-2OS 
and KHOS cell plate.
The efficiency of cellular uptake was examined at 2, 4, 
and 24 hours post-transfection. To determine the subcellular 
distributions of miR encapsulated in dextran-based nano-
particles, U-2OS cells transfected with 100 nM A546-let-7a 
encapsulated in dextran-based nanoparticles were visualized 
24 hours post-transfection under a Nikon Eclipse Ti-U fluo-
rescence microscope (Nikon Instruments, Inc., Melville, NY, 
USA) equipped with a SPOT RT™ digital camera (Diagnos-
tic Instruments, Inc., Sterling Heights, MI, USA). Just prior to 
microscopy, the cells were incubated with 1 µg/mL Hoechst 
33342 (Thermo Fisher Scientific) for 1 minute for nuclear 
counterstaining. Then, the cells were washed with PBS and 
visualized under microscope. Fluorescence intensity and 
cellular localization was analyzed in triplicate at different 
fields of view randomly.
MicrorNa real-time polymerase chain 
reaction assay
Osteosarcoma U-2OS cells were transfected with 100 nM of 
miR-199a-3p or let-7a encapsulated in dextran-based nano-
particles, or tranfected with Lipofectamine® RNAiMAX, or 
miR-199a-3p, or let-7a alone. The total RNA (including miRs) 
was extracted using an miRNANeasy Mini Kit (Qiagen NV) 
by following the manufacturer’s instructions 48 hours post-
transfection. The concentration of RNA was evaluated using a 
Beckman DU-640 spectrophotometer (Beckman Instruments, 
Inc., Fullerton, CA, USA). The quality of RNA was determined 
by 1% formaldehyde-agarose gel electrophoresis. An Applied 
Biosystems® TaqMan® MicroRNA Reverse Transcription Kit 
(Thermo Fisher Scientific) was used for quantification of miR 
expression. Complementary DNA reverse transcription was 
performed from total miR samples using specific miR primers 
of miR-199a-3p or let-7a from the TaqMan MicroRNA Assay 
Kits. Quantitative real-time polymerase chain reaction (PCR) 
was performed on an Applied Biosystems StepOne™ Real-
Time PCR System (Thermo Fisher Scientific) for 40 cycles 
(of 95°C for 15 seconds, 60°C for 15 seconds, and 72°C for 
30 seconds). Applied Biosystems RNU48 miR (Thermo 
Fisher Scientific) was used as endogenous control of miR 
expression. Untreated cells were used as reference samples. 
The relative gene-expression levels were then normalized by 
RNU48 and calculated using the Comparative CT (2^−ΔΔCt) 
method. The relative gene-expression levels were log10 
transformed prior to analysis. All experiments were carried 
out in triplicate.
Western blot analysis
Osteosarcoma U-2OS and KHOS cells were transfected with 
100 nM of miR-199a-3p encapsulated in dextran-based nano-
particles or transfected with Lipofectamine® RNAiMAX; or 
transfected with 100nM of Met siRNA (positive control) with 
Lipofectamine® RNAiMAX, nanoparticle or miR-199a-3p 
alone. Proteins were extracted from the transfected cells 
using 1× radioimmunoprecipitation assay (RIPA) lysis buf-
fer (Upstate Biotechnology, Lake Placid, NY, USA). The 
protein concentration was determined using protein assay 
reagents and standard protocols (Bio-Rad Laboratories, 
Hercules, CA, USA). Briefly, 25 µg of total protein was 
processed on Life Technologies NuPAGE® 4%–12% Bis-
Tris gel (Thermo Fisher Scientific) and transferred to a pure 
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, 
CA). After transfer, the membranes were blocked with 
Odyssey® Blocking Buffer (LI-COR Biosciences, Lincoln, 
NE, USA), and then incubated in primary antibodies buf-
fer (primary antibodies, Odyssey Blocking Buffer, 0.1% 
Tween® 20) overnight at 4°C. Three primary antibodies, 
insulin-like growth factor 1 receptor (IGF-1R), mammalian 
target of rapamycin (mTOR), and Met were purchased 
from Cell Signaling Technology, Inc. (Beverly, MA, 
USA). The following day, membranes were washed four 
times for 5 minutes in Tris-buffered saline and Tween 20 
(TBST). Subsequently, membranes were incubated 
in secondary antibodies IRDye® 680LT Goat Anti-Mouse 
lgG or IRDye 680LT Goat Anti-Rabbit lgG (LI-COR 
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Biosciences) plus Odyssey Blocking Buffer and 0.1% 
Tween 20 at 1:20,000 dilution for 1 hour. Finally, the mem-
branes were scanned on an Odyssey CLx imaging system, 
model:Ody-3086 (LI-COR Inc., Lincoln, NE).
cell proliferation assay
The effects of overexpression of miR delivered by dextran-
based nanoparticles on osteosarcoma cell proliferation were 
determined by 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide (MTT) assay. The cells were seeded at a 
density of 2,000 cells/well in 96-well culture plates and incu-
bated for 24 hours at 37°C prior to transfection. The follow-
ing day, cells were transfected with miR-199a-3p or let-7a 
encapsulated in dextran-based nanoparticles, or transfected 
with miR-199a-3p or let-7a Lipofectamine® RNAiMAX. 
After 96 hours, 20 mL of MTT solution (5 mg/mL 
in PBS) was added to each well. Samples were further 
incubated for 4 hours. The resulting formazan product 
was dissolved with HCL-isopropanol and the absorbance 
was read on a SpectraMax® microplate spectrophotom-
eter (Molecular Devices, LLC, Sunnyvale, CA, USA) at 
a wavelength of 490 nm. Experiments were carried out 
in triplicates. Cell growth curves were fitted with use of 
GraphPad PRISM4 software (GraphPad Software, Inc., 
La Jolla, CA).
statistical analysis
Student’s t-test was used to compare the differences between 
groups. Results are given as mean ± standard deviation and 
results with P0.05 are considered statistically significant.
Results
characterization of dextran nanoparticles 
encapsulated with microrNa
We previously developed a polymeric self-assembling 
nanoparticle system based on a functionalized dextran 
macrostructure to stably encapsulate siRNA molecules. 
In the current study, we used a similar method to encap-
sulate miRs. The selected miRs were incubated with the 
lipid-modified dextran (dextran-hexyl amine) derivative in 
deionized water at room temperature to form nanoparticles 
by self-assembly. Further, a thiolated-dextran derivative 
and a PEGylated-dextran
 
derivative were sequentially 
mixed with the miRs containing lipid-modified dextran to 
form intramolecular disulfide cross-linking of the dextran 
hydrogel network with protruding PEG chains to stabilize 
the individual nanoparticles. The method of sequential addi-
tion helped in the formation of stable nanoparticles with 
good miR entrapment.
The mean Z-average particle size (nm) of the miR-199a- 
3p-loaded nanoparticles was 351.6±2.5 nm (Figure 1A), as 
25
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Figure 1 characterization of microrNa encapsulated dextran nanoparticles.
Notes: (A) Z -average particles size (nm) and (B) apparent zeta potentials (mV) was determined by dynamic light scattering (Malvern Instuments Inc., Westborough, Ma) 
and (C) transmission electron microscopy of mir-199q-3p-loaded dextran nanoparticles was recorded using a JeM-1000 electron microscope ( JeOl ltd, Tokyo, Japan).
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determined by dynamic light scattering measurement, and 
the zeta potential was −25.3±7.47 mV (Figure 1B). The size 
of miR-199a-3p-loaded dextran nanoparticles was also char-
acterized and confirmed by transmission electron micrograph 
(Figure 1C). The miR particles were stable at room tempera-
ture and there was no significant change in particle size or 
zeta potential from storage (for up to 1 week at 4°C) in PBS. 
In addition the miR-loaded nanoparticels were amenable to 
lyophilization and stored at 4°C for prolonged periods.
cellular uptake of microrNas transfected 
with dextran-based nanoparticles
To assess the transfection efficacy of miR-loaded dextran 
nanoparticles on osteosarcoma cells, the cellular uptake of 
fluorescently labeled miR was assessed using a fluorescence 
microscope. Cells transfected with fluorescently labeled 
(AF488)-miR-199a-3p or (A546)-let-7a mixed with Lipo-
fectamine RNAiMAX were used as positive controls, and 
cells treated with AF488-miR-199a-3p or A546-let-7a alone 
were used as negative controls.
The results demonstrated that the dextran nanoparticles 
could efficiently transfect AF488-miR-199a-3p into U-2OS 
cells after 2 hours’ incubation, and the fluorescence signal 
increased with increasing duration of incubation time 
(Figure 2A–C). Interestingly, in comparison with miR trans-
fected using the commercial transfection agent (Lipofectamine; 
Figure 2D–F), dextran-based nanoparticles did not exhibit any 
apparent toxicity to the tumor cells and could promote miRs’ 
transfection into cells for longer duration of time. Similar 
results were observed for U-2OS cells transfected with A546-
let-7a miRs loaded in dextran nanoparticles (Figure S1).
In addition, subcellular distributions of A546-let-7a in 
dextran-based nanoparticle-transfected cells were also ana-
lyzed under fluorescence microscope. The results showed 
clear cytoplasmic distribution of fluorescently labeled A546-
let-7a miR. Similar to the observation with cells treated 
with miR-199a-3p loaded in dextran nanoparticles, cells 
transfected with dextran nanoparticles encapsulated with 
A546-let-7a miR also exhibited negligible toxicity com-
pared with cells transfected with miRs using Lipofectamine 
RNAiMAX (Figure S2).
These results demonstrate the advantages of using non-
toxic dextran-based nanoparticles for the efficient transfec-
tion of miRs into cancer cells.
2 h
AF488-miR199a-
3p/Nanoparticles
AF488-miR199a-
3p/Lipofectamine
4 h
24 h
miR199a-3p alone
A D G
C F I
B E H
Figure 2 Intracellular trafficking of microRNA encapsulated dextran nanoparticles in osteosarcoma cells.
Notes: Cellular uptake of fluorescently labeled AF488-miR-199a-3p encapsulated with dextran nanoparticles. U-2OS cells were transfected with AF488-miR199a-3p (green) 
encapsulated with dextran nanoparticle (A–C), with lipofectamineTM rNaiMax (D–F), or aF488-mir199a-3p alone (G–I). The cells were visualized by florescence 
microscopy at 2, 4, and 24 hours after transfection.
International Journal of Nanomedicine 2015:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2919
Nanoparticle delivery of mir in osteosarcoma
MicrorNa expression in dextran 
nanoparticle-transfected cells
After fluorescence microscopy showed that dextran nano-
particles are able to deliver fluorescently labeled miR into 
osteosarcoma cells, the expression of miR was further 
determined by real-time PCR with total RNA isolated from 
the osteosarcoma cells, as described in the “Materials and 
methods” section. The results indicate that miR-199a-3p 
(Figure 3A) and let-7a miR (Figure 3B) were significantly 
expressed in dextran nanoparticle-transfected osteosarcoma 
cells. The expression level of let-7a in U-2OS cells was 
also evaluated and confirmed at 24, 48, and 72 hours post-
transfection (Figure 3C).
MicrorNa-targeted gene protein 
expression in dextran nanoparticle-
transfected cells
It has been shown that mTOR and Met are direct targets of 
miR-199a-3p.11,13–15 To assess the functional role of miR 
delivered by dextran nanoparticles, the expression of target 
gene proteins in miR-199a-3p nanoparticle-transfected cells 
was measured using Western blotting. Relative mTOR and 
Met expression levels from the Western blot were analyzed 
by densitometry. The results show that nanoparticles encap-
sulated with miR-199a-3p can inhibit the expression of 
mTOR and Met in both U-2OS (Figure 4A and C) and KHOS 
(Figure 4B and D) osteosarcoma cell lines. As a control, Met 
siRNA can also decrease the expression of Met and have no 
effect on the expression of mTOR in both U-2OS and KHOS 
cell lines, as expected (Figure 4A–D).
effect on osteosarcoma cell growth 
and proliferation in dextran nanoparticle-
transfected cells
To determine whether transfection of dextran nanoparticles 
encapsulated miR-199a-3p or let-7a is able to alter the rate 
of cell proliferation and growth, osteosarcoma U-2OS and 
KHOS cells were transfected with miR-199a-3p or let-7a 
encapsulated with dextran-based nanoparticles, or trans-
fected with Lipofectamine® RNAiMAX. Non-specific miR 
mimic loaded in dextran based nanoparticles or mixed with 
Lipofectamine® RNAiMAX were used as controls. MTT 
assay showed that the delivery of miR-199a-3p (Figure 5A 
and C) or let-7a (Figure 5B and D) using dextran nano-
particles significantly decreased cell proliferation in both 
U-2OS (Figure 5A and B) and KHOS (Figure 5C and D) 
osteosarcoma cell lines. Furthermore, the inhibition of cell 
growth was dependent on the dose of miR, with the 100 nm 
concentration of miR exhibiting more potent inhibition than 
the 50 nm dose (Figure 5).
Discussion
miRs have been identified as playing a pivotal role in the 
regulation of key genes implicated in cancer maintenance, 
progression, and drug resistance.36 More recently, a number 
of research studies, both laboratory and clinic based, have 
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Notes: expression of mir-199a-3p or let-7a in osteosarcoma cells transfected by dextran nanoparticles. U-2Os cells were transfected with mir199a-3p (A) or 100 nM 
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Figure 4 Protein expression levels in osteosarcoma cells transfected with microrNas delivered using dextran nanoparticles.
Notes: Protein expression in mir-199a-3p dextran nanoparticle transfected osteosarcoma cells. U-2Os (A) and KhOs (B) cells were transfected with mir-199a-3p 
encapsulated with dextran-based nanoparticles, or transfected with lipofectamine® rNaiMaX. The expression of mTOr and Met were determined by Western blots, and 
the data were analyzed by densitometry (C and D).
Abbreviation: β-actin, beta-actin.
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reported on the implications of miRs in osteosarcoma.7,8,10,11 
Several research groups have shown that the expressions of 
miRs in osteosarcoma cells and in normal cells are signifi-
cantly different. Although these studies suggest that miRs 
have important roles in the development of osteosarcoma, 
the potential development of miRs as a therapeutic agent 
is largely unexplored. In this study, we demonstrated the 
exogenous transfection of miR-199a-3p into osteosarcoma 
cells using a dextran nanoparticle-based delivery system. 
The miR-199a-3p-encapsulated nanoparticles showed high 
miR transfection efficiency, significantly increased miR-
199a-3p expression, and decreased mTOR and Met expres-
sion, resulting in a suppression effect on osteosarcoma cell 
proliferation and growth. The dextran nanoparticles also 
showed good delivery efficiency for let-7a, another tumor-
suppressing miR.
Our group and others have previously shown that 
dextran-based nanoparticles are able to efficiently deliver 
both the chemotherapy drug doxorubicin as well as siRNA 
to osteosarcoma cells with no apparent toxicity.31–33,37 We 
also previously found that dextran-based nanoparticles 
can efficiently transport siRNA into tumor cells.32,33 More 
recently, cationized dextran nanoparticles encapsulated 
with C-X-C chemokine receptor type 4 (CXCR4) siRNA 
have been shown to significantly downregulate CXCR4 
expression in colorectal cancer, both in vitro and in vivo.38 
CXCR4 is highly overexpressed in various types of cancers. 
A dextran-based nanosystem containing epidermal growth 
factor receptor siRNA has also been successfully developed.39 
Furthermore, folates have been introduced as an active tumor-
targeting moiety to the hydroxyl groups of dextran to form 
dextran-siRNA conjugates. The data show that these dextran-
based nanosystems are very efficiently targeted to cancer cells 
and induce sequence-specific gene silencing.40
Our current study demonstrates – for the first time, as 
far as we are aware – that dextran nanoparticles are also 
capable of delivering miRs- with an efficiency similar to 
delivering siRNAs to cancer cells. By using two  different 
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Figure 5 Osteosarcoma cell growth inhibition using microrNa encapsulated dextran nanoparticles.
Notes: effect on osteosarcoma cell growth and proliferation in dextran nanoparticle transfected cells. U-2Os (A and B) and KhOs (C and D) cells were transfected with 
mir-199a-3p (A and C) or let-7a (B and D) encapsulated with dextran-based nanoparticles, or transfected with lipofectamine® rNaiMaX. MTT assay was performed by 
measuring the absorbance at a wavelength of 490 nm. Data are represented as means ± sD and analyzed using student’s t-test. *indicates P0.05.
Abbreviation: MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
A B
C D
A
bs
or
ba
nc
e
Hours Hours
Hours Hours
A
bs
or
ba
nc
e
A
bs
or
ba
nc
e
A
bs
or
ba
nc
e
1.5
1.0
0.5
0.0
0 20 40 60 80 100
0 20 40 60 80 100 0 20 40 60 80 100
0 20 40 60 80 100
1.5
1.0
0.5
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
**
*
*
*
*
*
**
*
*
*
*
*
*
miR-199a-3p/Nanoparticles (50 nM)
miR-199a-3p/Nanoparticles (100 nM)
miR-199a-3p/Lipofectamine
Mimic/Lipofectamine
Nanoparticles
U-2OS cells only
miR-199a-3p/Nanoparticles (50 nM)
miR-199a-3p/Nanoparticles (100 nM)
miR-199a-3p/Lipofectamine
Mimic/Lipofectamine
Nanoparticles
KHOS cells only
let-7a/Nanoparticles (50 nM)
let-7a/Nanoparticles (100 nM)
let-7a/Lipofectamine
Mimic/Lipofectamine
Nanoparticles
KHOS cells only
let-7a/Nanoparticles (50 nM)
let-7a/Nanoparticles (100 nM)
let-7a/Lipofectamine
Mimic/Lipofectamine
Nanoparticles
U-2OS cells only
fluorescently labeled miRs, AF488-miR-199a-3p (green) 
and A546-let-7a (red) encapsulated in dextran nanopar-
ticles, we tracked the intracellular uptake of miRs using 
fluorescence microscopy. Both AF488-miR-199a-3p 
and A546-let-7a could be visualized in the cytoplasm of 
osteosarcoma cells after transfection. miR-199a-3p and 
let-7a miRs were significantly expressed in the different 
dextran nanoparticle-transfected osteosarcoma cells, as 
demonstrated by real-time PCR.
More studies are needed to test the delivery efficiency 
of miR in vivo using these dextran nanoparticles. These 
studies will represent the first step toward the advancement 
of miR- and nanotechnology-based therapy strategies in 
combating osteosarcoma. In addition, the ability of dextran 
nanoparticles to transfect both miRs and siRNAs, as well 
as chemotherapy drugs, into cancer cells may represent a 
favorable multi-pronged approach to treating virulent dis-
eases such as multidrug-resistant tumors.
Conclusion
This study demonstrates the utility of using dextran-based 
nanoparticles to deliver miRs in cancer cells. Dextran-
based nanoparticles portend to be a promising platform to 
overcome the current limitations of miR delivery for the 
treatment of human cancers. However, the translation of 
these nanosystems for clinical use can be determined only 
after thorough in vivo evaluation in appropriate animal 
tumor models. The feasibility of such studies is underway 
in our laboratory.
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Supplementary materials
Figure S1 Cellular uptake of fluorescently labeled A546-let-7a encapsulated with dextran nanoparticles. U-2OS cells were transfected with 100 nM A546-let-7a (red) 
encapsulated with (A–C) dextran nanoparticles, (D–F) 100 nM a546-let-7a mixed with life Technologies lipofectamine® RNAiMAX (Thermo Fisher Scientific, Waltham, 
Ma, Usa), or (G–I) 100 nM A546-let-7a alone. The cells were washed with phosphate-buffered saline and visualized by fluorescence microscopy at 2, 4, and 24 hours after 
transfection.
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Figure S2 (Continued)
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Figure S2 Subcellular distributions of fluorescently labeled A546-let-7a. U-2OS cells were transfected with (A–C) dextran-based nanoparticles or (D–F) life Technologies 
lipofectamine® RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA). Twenty-four hours after transfection, the cells were incubated with 1 µg/ml hoechst 33342 for 
1 minute for nuclear counterstaining. Then, the cells were washed with phosphate-buffered saline and visualized under fluorescence microscope.
Abbreviation: mir, microrNa.
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